Company intelligence / Profile preview
Zai Lab
Shanghai, Chinazailaboratory.com ↗
- Ownership
- Public · ZLAB
- Employees
- ~2100
- Development stage
- Other
01
Overview
Zai Lab has built a broad pipeline of late-stage drug candidates, five of which have been approved and launched in China. The company is involved in 50+ ongoing or planned clinical trials globally, including 12 ongoing pivotal studies.
- Therapeutic areas
- OncologyImmunologyNeurologyInfectious Diseases
- Modalities
- Small moleculesBiologicsMonoclonal antibodiesAntibody-drug conjugates
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $2.5B
- Total revenue
- $460.2M
- Enterprise value
- $2.3B
Beyond the preview
Go deeper on Zai Lab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zai Lab.